WEX TTX-CINP-202

Condition: Neuropathic Pain

Neuropathic Pain

CINP: 1 study 

WEX TTX-CINP-202 - This is a randomized, double-blind, placebo-controlled, multicenter trial of the efficacy and safety of TTX in subjects with established CINP.  

Who’s Eligible/Study Details: 

• Adults 21+ 
• must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease 
• Hormone therapy is allowed, opioid and cytotoxic therapy is not 
• 13 Week duration total 
• 4-day BID injection 
• 90-day washout period for chemotherapy 

 

If you would like more information please contact clinical trials research coordinator at DJL Research in Charlotte 704-247-9179, x-207